Product
H2 Blocker
1 clinical trial
1 indication
Indication
Glycogen Storage Disease Type IIIClinical trial
A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD IIIStatus: Terminated, Estimated PCD: 2023-03-20